Literature DB >> 2864022

Twelve-year experience with bilateral internal mammary artery grafts.

D L Galbut, E A Traad, M J Dorman, P L DeWitt, P B Larsen, D Weinstein, J M Ally, T O Gentsch.   

Abstract

A 12 1/2-year experience with 227 patients who underwent coronary revascularization with bilateral internal mammary artery (IMA) and supplemental saphenous vein grafts is presented. There were 725 coronary grafts performed (3.2 per patient). Forty-four IMA grafts were sequential. In 42 patients, the right IMA was placed through the transverse sinus to revascularize the circumflex artery. Operative mortality was 4% (9 of 227 patients). Postoperative complications included sternal infection (4 patients), reexploration for bleeding (5), and diaphragmatic dysfunction (10). Postoperative arteriography in 30 patients (mean interval, 4 1/4 years) revealed that 92% (34/37) of the left IMA and 87% (26/30) of the right IMA grafts were patent. Late follow-up was complete in 207 surviving patients. Eighteen late deaths (9 cardiac and 9 noncardiac) occurred. Actuarial survival was 83% at 10 years after operation. Of 68 patients followed from 8 to 12 1/2 years (mean interval, 10 1/2 years), 69% were asymptomatic, and 28% were in New York Heart Association Functional Class II. We conclude that bilateral IMA grafting can be accomplished with low operative risk and provides excellent long-term results.

Entities:  

Mesh:

Year:  1985        PMID: 2864022     DOI: 10.1016/s0003-4975(10)60039-2

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  10 in total

1.  Sternal wound infections in patients after coronary artery bypass grafting using bilateral skeletonized internal mammary arteries.

Authors:  D Sofer; J Gurevitch; I Shapira; Y Paz; M Matsa; A Kramer; R Mohr
Journal:  Ann Surg       Date:  1999-04       Impact factor: 12.969

Review 2.  Thirty-year experience with bilateral internal thoracic artery grafting: where have we been and where are we going?

Authors:  Paul Kurlansky
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

Review 3.  Neo-intimal hyperplasia in vascular grafts and its implications for autologous arterial grafting.

Authors:  C Purcell; M Tennant; J McGeachie
Journal:  Ann R Coll Surg Engl       Date:  1997-05       Impact factor: 1.891

Review 4.  Atherosclerosis, inflammation, genetics, and stem cells: 2012 update.

Authors:  Pascal J Goldschmidt-Clermont; Chunming Dong; David M Seo; Omaida C Velazquez
Journal:  Curr Atheroscler Rep       Date:  2012-06       Impact factor: 5.113

5.  Genome-Wide Analysis of c-MYC-Regulated mRNAs and miRNAs and c-MYC DNA-Binding by Next-Generation Sequencing.

Authors:  Rene Jackstadt; Markus Kaller; Antje Menssen; Heiko Hermeking
Journal:  Methods Mol Biol       Date:  2021

6.  A comparison of early mortality and morbidity after single and bilateral internal mammary artery grafting with the free right internal mammary artery.

Authors:  S S Ashraf; N Shaukat; K Akhtar; H Love; J Shaw; D J Rowlands; D Keenan
Journal:  Br Heart J       Date:  1994-10

Review 7.  Targeting transcription cycles in cancer.

Authors:  Stephin J Vervoort; Jennifer R Devlin; Nicholas Kwiatkowski; Mingxing Teng; Nathanael S Gray; Ricky W Johnstone
Journal:  Nat Rev Cancer       Date:  2021-10-21       Impact factor: 60.716

Review 8.  Revascularization therapy for coronary artery disease. Coronary artery bypass grafting versus percutaneous transluminal coronary angioplasty.

Authors:  J M Wilson; J J Ferguson
Journal:  Tex Heart Inst J       Date:  1995

9.  Multivessel coronary revascularization with bilateral internal thoracic artery grafts.

Authors:  T Murakami; K Kino; Y Kioka; S Arai; K Kurozumi; Y Nakayama; S Indoh; Y Senoo; S Teramoto
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

10.  Reconstruction of coronary artery anomaly in an infant using the internal mammary artery: 10-year follow-up.

Authors:  D A Cooley; J M Duncan; P C Gillette; D G McNamara
Journal:  Pediatr Cardiol       Date:  1987       Impact factor: 1.655

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.